Silence Therapeutics (SLN) Equity Average (2019 - 2026)

Silence Therapeutics has disclosed Equity Average across 8 years of filings, most recently posting $55.9 million for Q1 2026.

• Equity Average for Q1 2026 came in at $55.9 million, down 54.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $55.9 million (down 54.73% YoY), and the FY2025 annual result was $98.2 million, up 25.84% from the prior year.
• Equity Average came in at $55.9 million for Q1 2026 at Silence Therapeutics, down from $68.2 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $149.6 million in Q2 2024 to a low of $18.7 million in Q4 2022.
• The 5-year median for Equity Average is $89.0 million (2024), against an average of $89.2 million.
• Across the five-year window, Equity Average soared 454.13% in 2024 and slumped 54.73% in 2026, its largest moves.
• Silence Therapeutics' Equity Average stood at $18.7 million in 2022, then increased by 25.86% to $23.5 million in 2023, then jumped by 454.13% to $130.4 million in 2024, then sank by 47.7% to $68.2 million in 2025, then retreated by 18.08% to $55.9 million in 2026.
• The last three Equity Average figures came in at $55.9 million (Q1 2026), $68.2 million (Q4 2025), and $84.1 million (Q3 2025), per Business Quant data.